Salom, EmeryPenalver, ManuelHomesley, HowardBurrell, MatthewGarrett, AudreyPresant, Cary ARutledge, JamesChernick, MichaelHallquist, AllanPerree, Mathieu2020-04-022020-04-022012-08-08http://hdl.handle.net/10342/7855This study was performed to determine if a chemotherapy-induced apoptosis assay (MiCK) could predict the best therapy for patients with ovarian cancer. A prospective, multi-institutional and blinded trial of the assay was conducted in 104 evaluable ovarian cancer patients treated with chemotherapy. The MiCK assay was performed prior to therapy, but treating physicians were not told of the results and selected treatment only on clinical criteria. Outcomes (response, time to relapse, and survival) were compared to the drug-induced apoptosis observed in the assay. The MiCK assay can predict the chemotherapy associated with better outcomes in ovarian cancer patients. This study quantifies outcome benefits on which a prospective randomized trial can be developed.Article10.1186/1479-5876-10-162